Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 565

1.

Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial.

Bilezikian JP, Hattersley G, Mitlak BH, Hu MY, Fitzpatrick LA, Dabrowski C, Miller PD, Papapoulos SE.

Curr Med Res Opin. 2019 Aug 16:1. doi: 10.1080/03007995.2019.1656955. [Epub ahead of print]

PMID:
31418585
2.

Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism.

Mannstadt M, Clarke BL, Bilezikian JP, Bone H, Denham D, Levine MA, Peacock M, Rothman J, Shoback DM, Warren ML, Watts NB, Lee HM, Sherry N, Vokes TJ.

J Clin Endocrinol Metab. 2019 Aug 1. pii: jc.2019-01010. doi: 10.1210/jc.2019-01010. [Epub ahead of print]

PMID:
31369089
3.

Therapy of Hypoparathyroidism with rhPTH(1-84): A Prospective Eight Year Investigation of Efficacy and Safety.

Tay YD, Tabacco G, Cusano NE, Williams J, Omeragic B, Majeed R, Almonte MG, Bilezikian JP, Rubin MR.

J Clin Endocrinol Metab. 2019 Jul 16. pii: jc.2019-00893. doi: 10.1210/jc.2019-00893. [Epub ahead of print]

PMID:
31310310
4.

Trabecular bone score: a useful clinical tool for the evaluation of skeletal health in women of short stature.

Alvarenga PPM, Silva BC, Diniz MP, Leite MB, da Silva CAM, de Cássia Mendes Eleutério J, Soares MMS, Bilezikian JP, Camargos BM.

Endocrine. 2019 Jul 13. doi: 10.1007/s12020-019-02002-y. [Epub ahead of print]

PMID:
31302886
5.

Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.

Bilezikian JP, Lin CJF, Brown JP, Wang AT, Yin X, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C, Chines A.

Osteoporos Int. 2019 Jun 14. doi: 10.1007/s00198-019-05020-8. [Epub ahead of print]

PMID:
31201481
6.

Three generational phenotypes of sporadic primary hyperparathyroidism: evolution defined by technology.

Cipriani C, Bilezikian JP.

Lancet Diabetes Endocrinol. 2019 Jun 3. pii: S2213-8587(19)30188-3. doi: 10.1016/S2213-8587(19)30188-3. [Epub ahead of print] No abstract available.

PMID:
31171450
7.

A STRATIFIED CROSS-SECTIONAL CLUSTER MODEL SURVEY OF IODINE NUTRITION IN ARMENIA AFTER A DECADE OF UNIVERSAL SALT IODIZATION.

Hutchings N, Aghajanova E, Baghdasaryan S, Qefoyan M, Sullivan C, He X, Manoukian M, van der Haar F, Gerasimov G, Braverman L, Bilezikian JP.

Endocr Pract. 2019 Jun 6. doi: 10.4158/EP-2018-0634. [Epub ahead of print]

PMID:
31170368
8.

Update on hypoparathyroidism.

Cusano NE, Bilezikian JP.

Curr Opin Rheumatol. 2019 Jul;31(4):381-387. doi: 10.1097/BOR.0000000000000618.

PMID:
31107289
9.

Chinese Women in Both the United States and Hong Kong Have Cortical Microstructural Advantages and More Trabecular Plates Compared With White Women.

Sum M, Zhu TY, Zhou B, Zhang Z, Bilezikian JP, Guo XE, Qin L, Walker M.

JBMR Plus. 2018 Nov 5;3(4):e10083. doi: 10.1002/jbm4.10083. eCollection 2019 Apr.

10.

Drugs for the treatment of metabolic bone diseases.

Drake MT, Cremers S, Russell RG, Bilezikian JP.

Br J Clin Pharmacol. 2019 Jun;85(6):1049-1051. doi: 10.1111/bcp.13857. Epub 2019 Apr 4. No abstract available.

PMID:
30950086
11.

Diagnostic Performance of 4D CT and Sestamibi SPECT/CT in Localizing Parathyroid Adenomas in Primary Hyperparathyroidism.

Yeh R, Tay YD, Tabacco G, Dercle L, Kuo JH, Bandeira L, McManus C, Leung DK, Lee JA, Bilezikian JP.

Radiology. 2019 May;291(2):469-476. doi: 10.1148/radiol.2019182122. Epub 2019 Mar 5.

PMID:
30835187
12.

Treated Osteoporosis Is Still Osteoporosis.

Lewiecki EM, Binkley N, Bilezikian JP.

J Bone Miner Res. 2019 Apr;34(4):605-606. doi: 10.1002/jbmr.3671. Epub 2019 Feb 19. No abstract available.

PMID:
30779859
13.

Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy.

Tabacco G, Tay YD, Cusano NE, Williams J, Omeragic B, Majeed R, Almonte MG, Rubin MR, Bilezikian JP.

J Clin Endocrinol Metab. 2019 Jul 1;104(7):2748-2756. doi: 10.1210/jc.2018-02430.

PMID:
30776291
14.

Vitamin D supplementation and musculoskeletal health.

Bouillon R, Lips P, Bilezikian JP.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):85-86. doi: 10.1016/S2213-8587(18)30348-6. No abstract available.

PMID:
30683216
15.

Management of normocalcemic primary hyperparathyroidism.

Cusano NE, Cipriani C, Bilezikian JP.

Best Pract Res Clin Endocrinol Metab. 2018 Dec;32(6):837-845. doi: 10.1016/j.beem.2018.09.009. Epub 2018 Sep 28. Review.

PMID:
30665550
16.

Pharmacology of bisphosphonates.

Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG.

Br J Clin Pharmacol. 2019 Jun;85(6):1052-1062. doi: 10.1111/bcp.13867. Epub 2019 Feb 28. Review.

PMID:
30650219
17.

Primary hyperparathyroidism.

Silva BC, Cusano NE, Bilezikian JP.

Best Pract Res Clin Endocrinol Metab. 2018 Sep 28:101247. doi: 10.1016/j.beem.2018.09.013. [Epub ahead of print] Review.

PMID:
30477754
18.

Primary hyperparathyroidism.

Silva BC, Cusano NE, Bilezikian JP.

Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):593-607. doi: 10.1016/j.beem.2018.09.004. Epub 2018 Sep 22. Review.

PMID:
30449543
19.

New Directions in Treatment of Hypoparathyroidism.

Tabacco G, Bilezikian JP.

Endocrinol Metab Clin North Am. 2018 Dec;47(4):901-915. doi: 10.1016/j.ecl.2018.07.013. Review.

PMID:
30390821
20.

Signs and Symptoms of Hypoparathyroidism.

Cusano NE, Bilezikian JP.

Endocrinol Metab Clin North Am. 2018 Dec;47(4):759-770. doi: 10.1016/j.ecl.2018.07.001. Review.

PMID:
30390811
21.

Controversies in Vitamin D: Summary Statement From an International Conference.

Giustina A, Adler RA, Binkley N, Bouillon R, Ebeling PR, Lazaretti-Castro M, Marcocci C, Rizzoli R, Sempos CT, Bilezikian JP.

J Clin Endocrinol Metab. 2019 Feb 1;104(2):234-240. doi: 10.1210/jc.2018-01414.

PMID:
30383226
22.

Proceedings of the 2018 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis.

Lewiecki EM, Bilezikian JP, Giangregorio L, Greenspan SL, Khosla S, Kostenuik P, Krohn K, McClung MR, Miller PD, Pacifici R.

J Clin Densitom. 2019 Jan - Mar;22(1):1-19. doi: 10.1016/j.jocd.2018.09.010. Epub 2018 Sep 22. Review.

PMID:
30366683
23.

Osteoanabolic and dual action drugs.

Tabacco G, Bilezikian JP.

Br J Clin Pharmacol. 2019 Jun;85(6):1084-1094. doi: 10.1111/bcp.13766. Epub 2019 Apr 3. Review.

PMID:
30218587
24.

Constituent analysis of iodine intake in Armenia.

Hutchings N, Aghajanova E, Baghdasaryan S, Qefoyan M, Sullivan C, He X, van der Haar F, Braverman L, Bilezikian JP.

Public Health Nutr. 2018 Nov;21(16):2982-2988. doi: 10.1017/S1368980018002197. Epub 2018 Sep 7.

PMID:
30189914
25.

Neonatal thyrotropin (TSH) screening as a tool for monitoring iodine nutrition in Armenia.

Hutchings N, Tovmasyan I, Hovsepyan M, Qefoyan M, Baghdasaryan S, Bilezikian JP.

Eur J Clin Nutr. 2019 Jun;73(6):905-909. doi: 10.1038/s41430-018-0298-4. Epub 2018 Aug 31.

PMID:
30171226
26.

MANAGEMENT OF ENDOCRINE DISEASE: Therapeutics of Vitamin D.

Ebeling PR, Adler RA, Jones G, Liberman UA, Mazziotti G, Minisola S, Munns CF, Napoli N, Pittas AG, Giustina A, Bilezikian JP, Rizzoli R.

Eur J Endocrinol. 2018 Oct 12;179(5):R239-R259. doi: 10.1530/EJE-18-0151. Review.

PMID:
30131372
27.

Re: A History of Pivotal Advances in Clinical Research Into Bone and Mineral Diseases.

Miller PD, Bilezikian JP, Lewiecki EM, Watts NB, Carey JJ.

J Bone Miner Res. 2018 Oct;33(10):1900-1901. doi: 10.1002/jbmr.3566. Epub 2018 Aug 29. No abstract available.

PMID:
30102788
28.

Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis.

Cipriani C, Pepe J, Silva BC, Rubin MR, Cusano NE, McMahon DJ, Nieddu L, Angelozzi M, Biamonte F, Diacinti D, Hans D, Minisola S, Bilezikian JP.

J Bone Miner Res. 2018 Dec;33(12):2132-2139. doi: 10.1002/jbmr.3554. Epub 2018 Aug 8.

PMID:
30088838
29.

AHNS Series: Do you know your guidelines? Optimizing outcomes in reoperative parathyroid surgery: Definitive multidisciplinary joint consensus guidelines of the American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons.

Stack BC Jr, Tolley NS, Bartel TB, Bilezikian JP, Bodenner D, Camacho P, Cox JPDT, Dralle H, Jackson JE, Morris JC 3rd, Orloff LA, Palazzo F, Ridge JA, Scott-Coombes D, Steward DL, Terris DJ, Thompson G, Randolph GW.

Head Neck. 2018 Aug;40(8):1617-1629. doi: 10.1002/hed.25023. Epub 2018 Aug 2.

PMID:
30070413
30.

Primary Hyperparathyroidism.

Bilezikian JP.

J Clin Endocrinol Metab. 2018 Nov 1;103(11):3993-4004. doi: 10.1210/jc.2018-01225.

PMID:
30060226
31.

The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry.

Rubin MR, Zhou H, Cusano NE, Majeed R, Omeragic B, Gomez M, Nickolas TL, Dempster DW, Bilezikian JP.

J Bone Miner Res. 2018 Nov;33(11):1931-1939. doi: 10.1002/jbmr.3543. Epub 2018 Aug 16.

32.

Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D.

Sempos CT, Heijboer AC, Bikle DD, Bollerslev J, Bouillon R, Brannon PM, DeLuca HF, Jones G, Munns CF, Bilezikian JP, Giustina A, Binkley N.

Br J Clin Pharmacol. 2018 Oct;84(10):2194-2207. doi: 10.1111/bcp.13652. Epub 2018 Jul 17. Review.

PMID:
29851137
33.

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.

Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Fitzpatrick LA, Mitlak B, Papapoulos S, Rizzoli R, Dore RK, Bilezikian JP, Saag KG.

J Clin Endocrinol Metab. 2018 Aug 1;103(8):2949-2957. doi: 10.1210/jc.2018-00163.

34.

Stop the war on DXA!

Lewiecki EM, Binkley N, Bilezikian JP.

Ann N Y Acad Sci. 2018 Dec;1433(1):12-17. doi: 10.1111/nyas.13707. Epub 2018 Apr 29.

PMID:
29707801
35.

IODINE NUTRITION IN THE REPUBLIC OF ARTSAKH (NAGORNO KARABAKH).

Hutchings N, Baghdasaryan S, Qefoyan M, Chiloyan A, Manoukian M, Atayan K, Bilezikian JP.

Endocr Pract. 2018 May;24(5):468-472. doi: 10.4158/EP-2018-0054. Epub 2018 Apr 24.

PMID:
29688765
36.

Epidemiology of hip fracture in Belarus: development of a country-specific FRAX model and its comparison to neighboring country models.

Ramanau H, Chernyanin I, Rudenka E, Lesnyak O, Zakroyeva A, Bilezikian JP, Johansson H, Harvey NC, McCloskey EV, Kanis JA.

Arch Osteoporos. 2018 Apr 17;13(1):42. doi: 10.1007/s11657-018-0454-4.

37.

Primary hyperparathyroidism: recent advances.

Walker MD, Bilezikian JP.

Curr Opin Rheumatol. 2018 Jul;30(4):427-439. doi: 10.1097/BOR.0000000000000511. Review.

PMID:
29664757
38.

Brown tumors of primary hyperparathyroidism may be a source of extrarenal 1,25-dihydroxyvitamin D production.

Sum M, Larner D, Hewison M, Bilezikian JP.

Endocrine. 2018 Jun;60(3):524-527. doi: 10.1007/s12020-018-1579-3. Epub 2018 Mar 19. No abstract available.

PMID:
29556950
39.

Pre-operative localization of abnormal parathyroid tissue by 99mTc-sestamibi in primary hyperparathyroidism using four-quadrant site analysis: an evaluation of the predictive value of vitamin D deficiency.

Tay YD, Yeh R, Kuo JH, McManus C, Lee JA, Bilezikian JP.

Endocrine. 2018 Apr;60(1):36-45. doi: 10.1007/s12020-018-1528-1. Epub 2018 Feb 5.

PMID:
29404903
40.

Trabecular Bone Score in Obese and Nonobese Subjects With Primary Hyperparathyroidism Before and After Parathyroidectomy.

Tay YD, Cusano NE, Rubin MR, Williams J, Omeragic B, Bilezikian JP.

J Clin Endocrinol Metab. 2018 Apr 1;103(4):1512-1521. doi: 10.1210/jc.2017-02169.

41.

New and developing pharmacotherapy for osteoporosis in men.

Gennari L, Bilezikian JP.

Expert Opin Pharmacother. 2018 Feb;19(3):253-264. doi: 10.1080/14656566.2018.1428559. Epub 2018 Jan 19. Review.

PMID:
29350069
42.

Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of Osteoporosis.

Lewiecki EM, Bilezikian JP, Carey JJ, Dell RM, Gordon CM, Harris ST, McClung MR, Miller PD, Rosenblatt M.

J Clin Densitom. 2018 Jan - Mar;21(1):3-21. doi: 10.1016/j.jocd.2017.10.041. Epub 2017 Nov 20.

PMID:
29229501
43.

Initiation of dapagliflozin and treatment-emergent fractures.

Toulis KA, Bilezikian JP, Thomas GN, Hanif W, Kotsa K, Thayakaran R, Keerthy D, Tahrani AA, Nirantharakumar K.

Diabetes Obes Metab. 2018 Apr;20(4):1070-1074. doi: 10.1111/dom.13176. Epub 2018 Jan 8.

PMID:
29193543
44.

Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.

Bilezikian JP, Hattersley G, Fitzpatrick LA, Harris AG, Shevroja E, Banks K, Leder BZ, Zanchetta JR, Hans D.

Osteoporos Int. 2018 Feb;29(2):323-328. doi: 10.1007/s00198-017-4304-9. Epub 2017 Nov 22.

45.

Epidemiology of fractures in Armenia: development of a country-specific FRAX model and comparison to its surrogate.

Lesnyak O, Sahakyan S, Zakroyeva A, Bilezikian JP, Hutchings N, Babalyan V, Galstyan R, Lebedev A, Johansson H, Harvey NC, McCloskey E, Kanis JA.

Arch Osteoporos. 2017 Nov 7;12(1):98. doi: 10.1007/s11657-017-0392-6.

46.

Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism.

Vokes TJ, Mannstadt M, Levine MA, Clarke BL, Lakatos P, Chen K, Piccolo R, Krasner A, Shoback DM, Bilezikian JP.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):722-731. doi: 10.1210/jc.2017-01471.

47.

Skeletal Microstructure and Estimated Bone Strength Improve Following Parathyroidectomy in Primary Hyperparathyroidism.

Cusano NE, Rubin MR, Silva BC, Tay YD, Williams JM, Agarwal S, Omeragic B, Guo XE, Bilezikian JP.

J Clin Endocrinol Metab. 2018 Jan 1;103(1):196-205. doi: 10.1210/jc.2017-01932.

48.

Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology.

Tay D, Cremers S, Bilezikian JP.

Br J Clin Pharmacol. 2018 Feb;84(2):252-267. doi: 10.1111/bcp.13455. Epub 2017 Dec 6. Review.

49.

Hypoparathyroidism.

Mannstadt M, Bilezikian JP, Thakker RV, Hannan FM, Clarke BL, Rejnmark L, Mitchell DM, Vokes TJ, Winer KK, Shoback DM.

Nat Rev Dis Primers. 2017 Oct 5;3:17080. doi: 10.1038/nrdp.2017.80.

PMID:
28980621
50.

Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25-μg or 50-μg Daily Doses.

Bilezikian JP, Clarke BL, Mannstadt M, Rothman J, Vokes T, Lee HM, Krasner A.

Clin Ther. 2017 Oct;39(10):2096-2102. doi: 10.1016/j.clinthera.2017.08.011. Epub 2017 Sep 21.

Supplemental Content

Loading ...
Support Center